Background data for the identification of protein biomarkers in CSF by proteomic approaches

Henning Grosskopf,Petra Steinacker,Markus Otto,Naguib Mechawar

DOI: https://doi.org/10.1016/j.psyneuen.2023.106707

IF: 4.693

2024-02-01

Psychoneuroendocrinology

Abstract:Background Protein biomarkers in cerebrospinal fluid (CSF) are a valuable tool for the differential diagnosis and follow-up of disorders affecting the central nervous system. However, no such biomarkers for depressive disorders are available so far. We aimed to facilitate the discovery of CSF biomarkers for depressive disorders by providing a background proteome of affected brain tissues and basic CSF sample parameters for discovery approaches. Methods The proteome of human post-mortem brain tissues from patients with major depressive disorder (MDD) and healthy controls were analyzed by high-resolution mass spectrometry. The resulting quantitative data were subjected to pathway and interaction network analyses. For basic CSF parameters, the reports for patients with MDD (N=217), bipolar disorder (N=29), schizophrenia (N=70), organic affective disorder (N=50), and healthy controls (N=37) were evaluated retrospectively. Results The proteome data for limbic brain tissues comprised relative quantitative data for ~4000 proteins, with about 10% being differentially abundant. A high gender difference was noticeable. Pathway and interaction analysis indicated altered protein hubs associated with synaptic trafficking and energy metabolism. CSF reports indicated blood-brain barrier dysfunction for up to 21% of psychiatric patients. Increased cell numbers and intrathecal immunoglobulin synthesis were found for up to 10%. Importantly, we identified patients with pathological Alzheimer’s disease biomarker levels. Conclusion Taken together, the data point to altered functionality in brain tissues affecting the composition of CSF and providing candidates as biomarkers for MDD. Co-morbidities influencing MDD biomarker candidate levels should be considered thoroughly in biomarker studies.

neurosciences,endocrinology & metabolism,psychiatry